Climb Bio, Inc. Announces $110.0 Million Private Placement
Rhea-AI Summary
Climb Bio (Nasdaq: CLYM) entered a private placement to raise approximately $110.0 million in gross proceeds, expected to close on or about April 29, 2026, subject to customary closing conditions.
The company is selling 9,481,000 common shares at $9.50 per share and issued pre-funded warrants to purchase up to 2,106,000 shares at $9.4999 each (exercise price $0.0001). Placement agents include Leerink Partners and Piper Sandler; several institutional investors participated. Climb Bio agreed to file a resale registration statement with the SEC within 45 days after closing.
Positive
- $110.0M gross proceeds expected from the private placement
- Participation from multiple institutional investors including RA Capital and Redmile
- Company will file resale registration within 45 days after closing
Negative
- Issuance and issuance-up-on-exercise totals 11,587,000 shares potentially outstanding
- Net proceeds reduced by placement agent fees and offering expenses
- Pre-funded warrants include beneficial ownership limits that may affect immediate conversion
News Market Reaction – CLYM
On the day this news was published, CLYM declined 2.53%, reflecting a moderate negative market reaction. Argus tracked a peak move of +16.8% during that session. Argus tracked a trough of -13.4% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $12M from the company's valuation, bringing the market cap to $453.80M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 08 | R&D webcast announcement | Neutral | +3.4% | Announcement of an R&D Spotlight webcast focused on budoprutug and CD19. |
| Apr 07 | Fast Track designation | Positive | +1.9% | FDA Fast Track designation for budoprutug in primary membranous nephropathy. |
| Mar 05 | Earnings and updates | Positive | +1.5% | Q4 and 2025 results with $160.7M cash and runway guidance into 2028. |
| Feb 05 | Conference participation | Neutral | -7.9% | Planned presentations at several investor conferences and related webcasts. |
| Jan 08 | Pipeline strategy update | Positive | +9.1% | Pipeline progress across budoprutug and CLYM116 and guidance for 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company news, especially clinical and corporate updates, has more often been followed by positive price reactions, with one notable negative move on a conference announcement.
Over the last few months, CLYM has generally reacted positively to company updates. A Fast Track designation for budoprutug on Apr 7, 2026 saw a +1.93% move, and a financial and business update on Mar 5, 2026 coincided with a +1.51% reaction. A broad pipeline and strategy update on Jan 8, 2026 drove a stronger +9.05% move. One exception was conference participation news on Feb 5, 2026, which was followed by a -7.92% decline.
Key Terms
private placement financial
institutional accredited investors financial
pre-funded warrants financial
beneficial ownership regulatory
registration statement regulatory
placement agents financial
resale registration statement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
WELLESLEY HILLS, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately
The private placement included participation from new and existing shareholders including Adage Capital Partners, L.P., ADAR1 Capital Management, Affinity Asset Advisors, LLC, Ally Bridge Group, Cormorant Asset Management, Driehaus Capital Management, Great Point Partners, LLC, RA Capital Management, Redmile, Sirenia Capital Management LP, Woodline Partners LP, and other institutional investors.
Leerink Partners and Piper Sandler are acting as lead placement agents in the private placement. Raymond James, BTIG, Baird, and H.C. Wainwright & Co. are also acting as placement agents in the private placement.
In the private placement, the Company is selling an aggregate of 9,481,000 shares of common stock at a purchase price of
The securities being sold in the private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) registering the resale of the shares of common stock issued in the private placement and the shares of common stock issuable upon exercise of the pre-funded warrants issued in the private placement no later than 45 days after the closing of the private placement.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.
About Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company with a mission to deliver high impact, disease-modifying medicines for individuals living with immune-mediated diseases, including those affecting kidney health. The Company’s pipeline includes, budoprutug, an anti-CD19 monoclonal antibody that has potential to treat a broad range of B-cell mediated diseases, and CLYM116, an anti-APRIL monoclonal antibody being developed for IgA nephropathy.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the anticipated closing of the private placement; the anticipated proceeds from the private placement; the anticipated timing for filing of a registration statement to register the resale of the shares and shares issuable upon exercise of pre-funded warrants to be issued and sold in the private placement; future expectations, plans and prospects for the Company; and other statements containing the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would,” “will,” “working,” and similar expressions. Forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in, or implied by, such forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. These risks and uncertainties include, but are not limited to, important risks and uncertainties associated with: the ability of the Company to timely and successfully achieve or recognize the anticipated benefits of its technology transfer and exclusive license agreement with Beijing Mabworks Biotech Co., Ltd.; changes in applicable laws or regulation; the possibility that the Company may be adversely affected by other economic, business and/or competitive factors; the Company’s ability to advance budoprutug and CLYM116 on the timelines expected or at all and to obtain and maintain necessary approvals from the U.S. Food and Drug Administration and other regulatory authorities; obtaining and maintaining the necessary approvals from investigational review boards at clinical trial sites and independent data safety monitoring boards; replicating in clinical trials positive results found in early-stage clinical trials and nonclinical studies; competing successfully with other companies that are seeking to develop treatments for primary membranous nephropathy, immune thrombocytopenia, systemic lupus erythematosus, IgA nephropathy and other immune-mediated diseases; maintaining or protecting intellectual property rights related to budoprutug, CLYM116 and/or its other product candidates; the outcome of any legal proceedings or other disputes; managing expenses; and raising the substantial additional capital needed, on the timeline necessary, to continue development of budoprutug, CLYM116 and any other product candidates the Company may develop. For a discussion of other risks and uncertainties and other important factors, any of which could cause the Company’s actual results to differ materially from those contained in the forward-looking statements, see the “Risk Factors” section, as well as discussions of potential risks, uncertainties and other important factors, in the Company’s most recent filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company’s views as of the date hereof and should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as required by law.
Investors and Media
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
